A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients - Van Cutsem, E; Prenen, H; D'Haens, G (Ann Oncol, 2015)
, et al.